ArticleEpilepsy currents
Extended-release formulations of antiepileptic drugs: rationale and comparative value.
Article in Epilepsy currents. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05641649 (Bioequivalence Study of Sodium Valproate and Valproic Acid Extended Release Tablets in Healthy Human Volunteers), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Bioequivalence Study of Sodium Valproate and Valproic Acid Extended Release Tablets in Healthy Human Volunteers
Who cites it
12 citing papers in PubMed, 47 citations in OpenAlex.
- USL255 extended-release topiramate: dose-proportional pharmacokinetics and tolerability in healthy volunteers.Epilepsia · 2014Trial
- Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial.Acta neurologica Scandinavica · 2014Trial
- Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults.British journal of clinical pharmacology · 2026Article
- Awareness of Risk Minimization Measures for Valproate and Pregnancy Prevention Program Compliance Among Pharmacists: A Cross-Sectional Survey in Romania.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Preparation and characterisation of PHT-loaded chitosan lecithin nanoparticles for intranasal drug delivery to the brain.RSC advances · 2020Article
- From clinical trials of antiepileptic drugs to treatment.Epilepsia open · 2018Article
- A Tailored Thermosensitive PLGA-PEG-PLGA/Emulsomes Composite for Enhanced Oxcarbazepine Brain Delivery via the Nasal Route.Pharmaceutics · 2018Article
- Not all that glitters is gold: A guide to the critical interpretation of drug trials in epilepsy.Epilepsia open · 2016Review
- Ghost-Pill-Buster: A Case Study of Intact Levetiracetam Extended-Release Tablets after Dissolution Testing.CNS drugs · 2016Article
- Pharmacokinetic characteristics of antiepileptic drugs (AEDs).The mental health clinician · 2016Article
- Epidural administration of neostigmine-loaded nanofibers provides extended analgesia in rats.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2014Article
- A Clinician's Guide to Oral Extended-Release Drug Delivery Systems in Epilepsy.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAGReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extended-release products are designed to prolong the absorption of drugs with short half-lives, thereby allowing longer dosing intervals while minimizing fluctuations in serum drug levels. The relationship between serum drug concentration and clinical effects of antiepileptic drugs (AEDs) can be complex and reducing fluctuations in serum drug levels is not equally advantageous for all AEDs. Extended-release formulations have been shown to be particularly valuable for carbamazepine, whereas for other AEDs advantages, other than prolongation of the dosing interval, have not been clearly demonstrated. Differences in bioavailability may exist between extended-release and immediate-release formulations and among different brands of extended-release products. Therefore, when switching from one formulation to another, careful monitoring of clinical response and attention to the need for dose adjustment are warranted.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.